Aarti Pharmalabs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹583Cr
- +3.4% YoY
- +35% QoQ
- Net profit
- ₹61Cr
- −30.7% YoY
- +27.1% QoQ
- Margin
- 19%
- −7 pp YoY
- −5 pp QoQ
Guidance rank: #5 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
From Aarti Pharmalabs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years.
- CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth.
- Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth.
- API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues.
- Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards.
2 more points from Aarti Pharmalabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
- Capex for dedicated manufacturing block is included but the exact amount is still being finalized.
- Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up.
- Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters.
- Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027.
2 more points from Aarti Pharmalabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has 21 active CDMO customers, a number steady over the last five quarters.
- Engagements with these customers are ongoing for newer projects, indicating pipeline development.
- In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now.
- The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders.
- Capex decisions for custom-built facilities are based on sensible forecasts from customers.
2 more points from Aarti Pharmalabs Ltd's call on order book
Create a free account to keep reading this call
Aarti Pharmalabs Ltd — Quarterly revenue & net profit
Aarti Pharmalabs Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 583 | 564 | +3.4% | 432 | +35% |
| Operating profit (EBITDA) | 113 | 146 | -22.6% | 102 | +10.8% |
| Operating margin | 19% | 26% | -7 pp | 24% | -5 pp |
| Profit before tax | 82 | 115 | -28.7% | 63 | +30.2% |
| Net profit (PAT) | 61 | 88 | -30.7% | 48 | +27.1% |
| EPS (₹) | 6.74 | 9.75 | -30.9% | 5.29 | +27.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Pharmalabs Ltd Q4 FY26 results?
The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.
What is Aarti Pharmalabs Ltd share price analysis?
Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharmalabs Ltd planning capital expenditure?
Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
